Scythian Biosciences Management Presentation

1. Management Presentation
February 2017
Private and Confidential

2. Disclaimer
This presentation and the information contained herein are confidential and the property of
Scythian Biosciences Inc. This presentation is intended to introduce you to Scythian.
The information presented is not, and is not intended to be, an offer to sell or the solicitation of an
offer to buy any security of Scythian. It does not constitute an offer, solicitation or sale of any
securities of Scythian. It is not a prospectus or an offering memorandum.
Statements made are as of the date hereof; delivery of this presentation does not at any time create
an implication that the information contained herein is accurate as of any date subsequent to
today’s date. Scythian has not undertaken any independent verification of industry data, trends, or
third party information used herein.
This presentation contains forward looking information. These statements relate to future events
and future performance. Forward-looking statements are based on the opinions and assumptions of
management as of the date made, and are subject to a variety of risks and other factors that could
cause actual events/results to differ materially from these forward looking statements.
Although management believes that the expectations are reasonable, there can be no assurance
that such expectations will prove to be correct; these statements are no guarantee of future
performance and involve known and unknown risks, uncertainties and other factors. We cannot
guarantee future results, performance, or achievements and no representations are made that actual
results achieved will be the same. Nothing herein can be assumed or predicted, and readers are
strongly encouraged to learn more and seek independent advice before relying on any information
presented.
2Private and Confidential

3. The Opportunity
“The awareness of the consequences that arise from mild traumatic brain
injuries (mTBI), commonly referred to as concussions, has been on the rise and
is a “hot topic” in the media, medicine, and basic research. In light of
increasing awareness, a clear understanding of the immediate and long-term
neural pathology underlying a concussive injury is incomplete thereby
precluding both proper assessment and suitable treatment strategies.”
-Frontiers in Cellular Neuroscience
3
Research & Development
Team led by Board
Certified Neurologist at
University of Miami
Relationship of Cannabinoids
To Traumatic Brain Injury
NFL Alumni and World
Boxing Association

4. Company Overview
4Private and Confidential
 Committed to finding a solution for the prevention and treatment of concussions and
traumatic brain injury with its proprietary Cannabinoid ("CBD") combination
 Recently formed a collaboration with the University of Miami and its world renowned
neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen
 Scythian is endorsed by the NFLAlumni Association and the World Boxing Association on
its mission
 Equal opportunity injury — affecting athletes ranging from NFL Football to youth Lacrosse
 Patented process and formulation emerging from innovative clinical research
 Growing acceptance of cannabinoids as a medical breakthrough
 Based in Calgary, Canada
Scythian's mission is to be the first accepted drug regimen for
concussive treatment

5. Our Patent and the
Use of Cannabinoids
 Methods and Compositions for treating Traumatic Brain Injury
 The use of Cannabinoids as part of formulation
 The Cannabinoid CB-2 receptor has been disclosed as a target for inflammation-
dependent neurodegenration
 CBD is a naturally occurring chemical in certain varieties of Marijuana
 CBD has no psychoactive effect
 CBD acts as a CB-2 agonist and presents a broad range of anti-inflammatory and
immune inhibitory effects
Private and Confidential 5

6. UConcussion Program:
Teaming Up to Fulfill a Mission
 The “UConcussion Treatment & Management Program” at the University of Miami,
is widely recognized as the foremost source for treating concussions and head trauma.
 Dr. Gillian A. Hotz, PhD, a leading research professor at the University of Miami’s
School of Medicine, has been the Co-Director of the Concussion Program for twenty
years. Dr. Hotz is nationally recognized as a behavioral neuroscientist and expert in
pediatric and adult neurotrauma and concussion management.
 The parties have been working collaboratively to clinically test Scythian’s patent which
is comprised mainly of Cannabinoids.
 Our end goal is to develop the first pharmacologically based drug regimen that
successfully treats head trauma and concussions.
 We are now in Pre-Clinical Trials and hope to reach Phase 1 next year.
6Private and Confidential
•Education of athletes, parents,
Coaches and ATCs
•Using Student Leadership,
Involvement and Community
Engagement (SLICE)
•Training workshops
• Program Planning
•Implementation
•Baseline & Sideline testing
•Clinical Exam
• Evaluate program effectiveness
•Pre & Post testing
•Injury Surveillance tracking
incidents & recovery
The Model

7. Sports Concussions
 Concussions among teens ages 14-19 have risen 200% since 2005(3)
 Cumulative sports concussions increase the likelihood of permanent neurologic
disability by 39% (3)
 While football accounts for 47% of all sports concussions (followed closely by ice
hockey and soccer), 15 different sports indicate at least 7% of their athletes are at risk
for serious head trauma (3)
7Private and Confidential
Reported sports-related concussions top 3.8 million; yet most go undiagnosed(1)
(1) Dr. David Dodick, M.D., neurologist, Mayo Clinic Arizona. An internationally recognized expert on concussion
(2) Center for Disease Control
(3) American Academy of Pediatric
 Over the past decade the number of reported concussions
has doubled(2)
 Emergency room visits for children 8-13 with sports
concussion doubled from 1997-2007 (3)

8. Industry Comparables
8Private and Confidential
Market Capitalization
(As at February 22nd, 2017)
(in USD millions)
Products
Market Phase 3 Phase 2
$3,262 1 3 4
- 1 -
- - 2
- - 1
- - -
- - 1
- - -
$27
(1)
(1) Phase 3 clinical research is process in Israel

9. Management Team
 Jonathan Gilbert - Founder, Chief Executive Officer and Director
 President, Gilbert Capital Management Corp. — Investment Advisors
 Chief Marketing Officer, Commonwealth Opportunity Capital — hedge fund
 B.B.A. in Finance, George Washington University
 David Schrader - Chief Operating Officer and Director
 Experienced Business Attorney and Corporate Executive. Currently a Partner at Moritt Hock & Hamroff LLP.
Previously: Fried Frank Harris Shriver & Jacobson; Wolff & Samson; Laconia Capital; K-Tex, LLC.
 MBA, M.Sc. in Global Management, M.Sc. in Strategic Management, Juris Doctorate, LL.M. in business
transactions, B.A. Biochemistry/molecular biology from John Hopkins University.
 Additional expertise in Supply Chain Management, Bioethics and International business.
9Private and Confidential

10. Advisory Board
 Maghsoud Dariani
 Founder team member, and Vice President of Celgene
Corporation
 Responsible for Celgene’s Manufacturing Strategy,
Chiral Pharmaceutical Business
 CEO of Semorex Cancer Therapy and President of
Focus Pharmaceuticals
 Board of Directors, numerous public companies
 Bart Oates
 President, NFL Alumni Association
 Magna Cum Laude, Juris Doctorate, Seton Hall Law
School
 5-time NFL Pro Bowl player; 3-time Super Bowl
Champion
10Private and Confidential
 Peter Levy, Esq.
 COO and President of two publicly traded
companies
 Integrity Monitor, Securities and
Exchange Commission
 Expert in Internal Controls and Corporate
Governance
 Attorney with over 25 years experience
 Scott David Boruchov
 Radiology, Edison Radiology Group
 Facility Director Advanced Medical Imaging
 Tremendous Access to Head Trauma
Patients

11. In the Public Media
11Private and Confidential
“Kansas football player dies after collapsing at game”
“Chicago teen becomes seventh high school football player to die this year”
“High school football player dies after suffering head injuries during game”
“Another high school football player dies”
“High school football player Andre Smith dies in Illinois”
“NJ High school star quarterback dies after suffering injury during game”
“‘Great kid, athlete’ dies after high school football game”

12. Contact Information
Jonathan Gilbert, CEO
Email: jgilbert@scythianbio.com
Phone: 917-693-0215